HighTower Advisors’s RAPT Therapeutics RAPT Stock Holding History

HighTower Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,525	Closed	-$424K	–	3909
2025 Q4	$424K	Sell	12,525 -100	-0.8%	-$3.11K	﹤0.01%	2756
2025 Q3	$326K	Buy	+12,625	New	+$165K	﹤0.01%	2978

HighTower Advisors's RAPT Position: Q1 2026 in Review

HighTower Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 12,525 shares — an estimated $424K sold.

HighTower Advisors first reported a position in RAPT in Q3 2025 and held it in 2 quarters. The position peaked at $424K in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

HighTower Advisors reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
HighTower Advisors sold 12,525 RAPT Therapeutics shares in Q1 2026, an estimated $424K.
HighTower Advisors first reported a position in RAPT Therapeutics in Q3 2025 and held it in 2 quarters.
HighTower Advisors's RAPT Therapeutics position peaked at $424K in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.